Business ❯ Healthcare ❯ Pharmaceuticals

Drug Sales

Eli Lilly Johnson & Johnson Merck & Co Weight Loss Drugs Multiple Sclerosis Drugs Weight-loss Drugs Dupixent Immunology Drugs Revenue Generation Merck & Co. GLP-1 Drugs Merck Regeneron Pharmaceuticals Weight-loss and Diabetes Drugs Eli Lilly & Co. Novo Nordisk Cancer Treatments Weight-loss Treatments Weight Loss Medications Eliquis Rare Disease Drugs

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

A one-time deal cost turned a strong sales quarter into a loss.

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Novo Nordisk Strikes Hims & Hers Deal for Ozempic and Wegovy, Drops Patent Suit

AbbVie Beats Q4 and Raises 2026 Outlook as Shares Fall on Aesthetics, Oncology Concerns

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

Dupixent Powers Sanofi’s Q3 as Vaccine Sales Slip